Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.
Morgan Alvah, PharmD
Advertisement
Articles by Morgan Alvah, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
2
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
3
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
4
Expert Discusses Early Safety and Tolerability Findings for VMT-α-NET in Neuroendocrine Tumors | ESMO 2025
5
